ArticleFrontiers in oncology2026
Multidisciplinary team care and outcomes in FNCLCC grade 3 soft tissue sarcoma: a propensity score-matched and weighted cohort study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multidisciplinary team (MDT) care is widely advocated for soft tissue sarcoma (STS), yet real-world evidence in high-grade disease remains limited and subject to confounding. We investigated whether pre-treatment MDT care was associated with improved outcomes in FNCLCC grade 3 STS. Methods: This retrospective cohort study included consecutive adults with pathologically confirmed FNCLCC grade 3 STS treated at the Department of Orthopaedics, Cancer Hospital, Chinese Academy of Medical Sciences (2010-2022). MDT care was defined as formal discussion after pathological diagnosis and before definitive treatment. Primary endpoints were 3-year local recurrence and distant metastasis from diagnosis (administrative censoring at 36 months). Propensity scores were estimated using logistic regression; confounding was addressed using 1:1 propensity score matching (PSM) and stabilized inverse probability of treatment weighting (IPTW). Odds ratios (ORs) and Kaplan-Meier analyses were applied. Results: Among 338 patients (MDT, n=88; non-MDT, n=250), MDT care was associated with lower 3-year local recurrence (6.8% vs 21.2%; unadjusted OR = 0.272, P = 0.002), with consistent results after PSM (paired OR = 0.259, P = 0.021) and IPTW (OR = 0.296, P = 0.008). By contrast, 3-year distant metastasis did not differ significantly between groups in unadjusted, matched, or weighted analyses (weighted OR = 0.846, 95% CI 0.418-1.714; P = 0.643), although the confidence interval did not exclude a potentially moderate clinically meaningful benefit. Conclusions: In FNCLCC grade 3 STS, pre-treatment MDT care was associated with improved 3-year local control but not with a significant reduction in 3-year distant metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.